Hutchison China Meditech Ltd (HCM)

25.88
0.38 1.49
NASDAQ : Health Care
Prev Close 25.50
Open 25.57
Day Low/High 25.26 / 25.88
52 Wk Low/High 9.80 / 14.70
Volume 29.75K
Avg Volume 26.40K
Exchange NASDAQ
Shares Outstanding 121.47M
Market Cap 3.10B
EPS 0.10
Div & Yield N.A. (N.A)

Latest News

Chi-Med Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL-453 in China.

Chi-Med Highlights Phase III Fruquintinib Data In Oral Presentation At ASCO

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial growth factor receptor ("VEGFR") kinase inhibitor, were...

Chi-Med Presents Clinical Data At ASCO 2017 Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and sulfatinib, will be presented at the 2017...

Chi-Med Presented Pre-clinical Data For Fruquintinib And Sulfatinib At The American Association For Cancer Research Annual Meeting 2017

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Cancer Research ("AACR") Annual Meeting 2017, held in Washington, D.

Presidents Trump and Xi Have 3 Major Issues to Discuss This Week

Presidents Trump and Xi Have 3 Major Issues to Discuss This Week

Currency manipulation, dumping and intellectual property are crucial themes for the meeting.

Chi-Med To Host R&D Briefings On March 29 & 30, 2017

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an overview of the Company's clinical...

Chi-Med: Grant Of Awards Under Long Term Incentive Plan

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards ("LTIP Awards") under the Long Term Incentive Plan ("LTIP") adopted by Chi-Med at its Annual...

Publication Of Annual Report And Financial Results For The Year Ended December 31, 2016

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced today that on Monday March 13, 2017, it filed its annual report ("Annual Report") on Form 20-F with the U.

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results At The 14th Annual Conference Of European Neuroendocrine Tumor Society

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) presented data from the ongoing Phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine tumors ("NET") at the 14th Annual Conference...

Chi-Med Announces Positive Top-Line Results For FRESCO, Its Phase III Pivotal Registration Trial Of Fruquintinib In Patients With Locally Advanced Or Metastatic Colorectal Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic...

Chi Med Appoints Graeme Jack As Independent Non-executive Director And Chairman Of Audit Committee

Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- 1.

Chi-Med Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carcinoma ("PSC") in China.

Chi-Med And AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results At 2017 Genitourinary Cancers Symposium

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) and AstraZeneca PLC ("AstraZeneca") will present data from the ongoing Phase II clinical trial of savolitinib in patients with papillary renal cell carcinoma...

Chi-Med Initiates First-In-Human Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In Australia

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human ("FIH") Phase I clinical trial of HMPL-453 in Australia.

Chi-Med Appoints Industry Veteran Karen Ferrante To Board Of Directors

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today:- 1.

Chi-Med Appoints Industry Veteran Paul Carter To Board Of Directors

Chi-Med Appoints Industry Veteran Paul Carter To Board Of Directors

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Executive Director and member of the...

Chi-Med Presents Phase I/II Clinical Data For Selective VEGFR Inhibitor Fruquintinib At The 2017 Gastrointestinal Cancers Symposium

Chi-Med Presents Phase I/II Clinical Data For Selective VEGFR Inhibitor Fruquintinib At The 2017 Gastrointestinal Cancers Symposium

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol ®) in second-line patients with...

Chi-Med Initiates A Phase II Study Of Sulfatinib In Second-line Biliary Tract Cancer In China

Chi-Med Initiates A Phase II Study Of Sulfatinib In Second-line Biliary Tract Cancer In China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer ("BTC") patients in China.

Chi-Med Initiates A Phase II Combination Study Of Fruquintinib With Iressa® (gefitinib) In First-Line Non-Small Cell Lung Cancer

Chi-Med Initiates A Phase II Combination Study Of Fruquintinib With Iressa® (gefitinib) In First-Line Non-Small Cell Lung Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa ® in the first-line setting for patients with...

Chi-Med Initiates HMPL-523 Clinical Trials In Hematological Cancer In China

Chi-Med Initiates HMPL-523 Clinical Trials In Hematological Cancer In China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase ("Syk") inhibitor, HMPL-523, in patients with hematological...

Chi-Med Presents Pre-clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 American Society Of Hematology Annual Meeting

Chi-Med Presents Pre-clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 American Society Of Hematology Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spleen Tyrosine Kinase...

Chi-Med To Present Data From Proof-of-Concept Clinical Trials For Fruquintinib And Epitinib At The 17th World Conference On Lung Cancer (

Chi-Med To Present Data From Proof-of-Concept Clinical Trials For Fruquintinib And Epitinib At The 17th World Conference On Lung Cancer ("WCLC")

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer ("NSCLC") clinical studies will be presented at WCLC in Vienna, Austria, from December 4 to 7,...

Chi-Med Presents Phase I Clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 ACR/ARHP Annual Meeting

Chi-Med Presents Phase I Clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 ACR/ARHP Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokinetics ("PK") and...

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its 50:50 Prescription Drug joint venture with a subsidiary of Shanghai Pharmaceuticals...

ZTO Express, One of Alibaba's Largest Shippers, Has Great Timing For U.S. Listing

ZTO Express, One of Alibaba's Largest Shippers, Has Great Timing For U.S. Listing

The company that ships packages for Jack Ma's e-commerce giant is ready to follow suit with a public listing in the U.S.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.

Hutchison China MediTech Limited (

Hutchison China MediTech Limited ("Chi-Med"): Change Of Non-executive Directors

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who has tendered...

Hutchison China MediTech Limited (

Hutchison China MediTech Limited ("Chi-Med") Reports Interim Results For The Six Months Ended June 30, 2016, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs

Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market, today announces its unaudited...